Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Sanofi's Investigational Semuloparin in Cancer Patients Initiating Chemotherapy Shows a 64 % Risk Reduction in Life-Threatening Venous Thrombo-Embolism
Sanofi's Investigational Semuloparin in Cancer Patients Initiating Chemotherapy Shows a 64 % Risk Reduction in Life-Threatening Venous Thrombo-Embolism
Sanofi's Investigational Semuloparin in Cancer Patients Initiating Chemotherapy Shows a 64 % Risk Reduction in Life-Threatening Venous Thrombo-Embolism
Submitted by
admin
on June 4, 2011 - 10:29am
Source:
Yahoo/PR NewsWire
News Tags:
Sanofi
Semuloparin
Venous Thrombo-Embolism
Headline:
Sanofi's Investigational Semuloparin in Cancer Patients Initiating Chemotherapy Shows a 64 % Risk Reduction in Life-Threatening Venous Thrombo-Embolism
Do Not Allow Advertisers to Use My Personal information
